Business context and reporting period
Nova Measuring Instruments Ltd. filed this annual report on Form 20-F for the fiscal year ended December 31, 2013. It designs and sells integrated and stand-alone optical metrology systems and related services for semiconductor manufacturing. Financial statements are prepared under U.S. GAAP and reported in U.S. dollars. This is an annual filing, not a standalone fourth-quarter report; the filing text does not provide a clear set of Q4-only financial results.
Key financial metrics
Amounts below are in millions of U.S. dollars unless stated otherwise.
| Metric | 2013 | 2012 |
|---|---|---|
| Revenue | $111.5 | $96.2 |
| Gross profit / gross margin | $59.1 / 53.0% | $51.2 / 53.2% |
| Operating income / operating margin | $12.3 / 11.1% | $10.6 / 11.0% |
| Net income / net margin | $10.5 / 9.4% | $11.8 / 12.3% |
| Diluted EPS | $0.38 | $0.43 |
| Cash from operating activities | $11.0 | $7.7 |
| Cash, cash equivalents and bank deposits | $97.8 | $91.4 |
| Working capital | $118.6 | $106.3 |
| Total assets / shareholders’ equity | $162.3 / $128.7 | $142.0 / $114.8 |
The $97.8 million cash-and-deposits figure is derived from balance-sheet cash and cash equivalents, short-term deposits and long-term deposits; management separately describes total cash reserves, including short-term securities, as $99.7 million. The company reported no significant long-term debt and no readily available long-term credit line. 2013 capital expenditures were $4.1 million; management expected approximately $8 million in 2014.
Material changes versus 2012
- Revenue rose 16% to a record $111.5 million, following a 6.5% decline in 2012. Product revenue increased 16% and service revenue 17%.
- Operating income increased about 17%, but net income declined about 11% as income-tax expense rose to $2.5 million from $0.1 million. Diluted EPS fell from $0.43 to $0.38.
- Gross margin edged down to 53.0% from 53.2%. Product gross margin declined to 58% from 59%, while service gross margin improved to approximately 34% from 30%.
- Net R&D expense increased 20% to $29.6 million, or 26.5% of revenue, reflecting added personnel and subcontracting for the product roadmap. G&A expense increased 31% to $5.2 million, partly due to employee costs and a one-time senior-executive retirement provision.
- Operating cash flow increased to $11.0 million, although trade receivables rose to $27.9 million from $17.4 million, largely due to higher fourth-quarter sales. Inventory was $18.1 million, little changed from $17.8 million.
Outlook, commentary, risks and unusual items
- Management planned continued growth, product development and market-share gains in 2014, with emphasis on foundry and memory customers, advanced technology nodes, 3D structures, software products and 450mm-wafer development. It expected to expand R&D spending. These are plans, not company revenue or earnings guidance.
- The filing cites Gartner’s December 2013 forecast of 16.4% growth in 2014 wafer-fab-equipment spending. Nova said it believed it was positioned to benefit; actual results depend on cyclical industry investment and customer demand.
- Key exposures include reliance on two main product lines, concentrated customers and products (the five largest customers accounted for 72% of 2013 revenue; one customer accounted for 44%), semiconductor-industry cyclicality, intense competition, technology transitions, cancellable or delayed orders, and a single manufacturing facility in Israel.
- More than 95% of cash reserves were held with Israeli banks, with approximately half at one institution. Currency risk is material because revenue is mainly in U.S. dollars while substantial expenses are in shekels; the company used forward contracts and currency options. Management estimated a 10% NIS depreciation would reduce the fair value of foreign-currency net assets by about $1.0 million.
- Inventory write-offs were $1.8 million in 2013. OCS development grants carry royalties of 3%–3.5% on relevant product sales; the financial-statement note reports a contingent balance of approximately $21.4 million at year-end. Repayment depends on future sales.
- Management and the independent auditor concluded internal control over financial reporting was effective at December 31, 2013. The auditor issued unqualified opinions on the financial statements and internal controls. No significant legal proceedings were reported. Nova did not expect to pay cash dividends for at least several years.
Important facts for investors to verify
- Customer concentration: verify the 44% revenue contribution from the largest customer and the stability of major-customer orders.
- Cash availability and counterparty risk: reconcile the reported $99.7 million cash reserves with balance-sheet cash, deposits and securities, and assess bank concentration.
- Receivables and cash conversion: track collection of the year-end receivables increase and operating cash flow relative to earnings.
- Margin and expense trends: assess whether rising R&D investment and product mix support future growth without further profit erosion.
- 2014 execution and market assumptions: compare actual performance with management’s plans and the cited industry-spending forecast; the filing provides no quantified company guidance.
- Contingencies and unusual items: review OCS royalty obligations, inventory write-offs, tax assumptions and the senior-executive retirement provision.